Plasminogen activation system

Festuccia, C, V Dolo, F Guerra et al. 1998. Plasminogen activator system modulated invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16 513-528. [Pg.460]

Ferrier CM, van Geloof WL, de Witte HH, et al. Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. J. Histochem. Cytochem. 1998 46 469-476. [Pg.21]

Duffy MJ. 2004. The urokinase plasminogen activator system Role in malignancy. Curr Pharm Des 10 39-49. [Pg.179]

Hajjar, K.A., and S. Krishnan, 1999, Annexin II a mediator of the plasmin/plasminogen activator system. Trends Cardiovasc. Med. 9, 128-138. [Pg.22]

Ronne E, Behrendt N, Ellis V, Ploug M, Dano K, Hoyer-Hansen G. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett 1991 ... [Pg.93]

Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000 57(l) 25-40. [Pg.93]

Pappot H. The plasminogen activation system in lung cancer—with special reference to the prognostic role in non-small cell lung cancer. APMIS Suppl 1999 92 1-29. [Pg.101]

The urokinase-plasminogen activator system consists of three main components, urokinase-plasminogen activator (uPA, a 53kDa serine protease), the uPA membrane-bound receptor (uPAR), and the uPA inhibitors, PAI-1 and PAl-2 5 3XB2,185... [Pg.761]

Andreasen PA, Kjoller L, Christensen L, et al. The Urokinase-type plasminogen activator system in cancer metastasis a review. Int J Cancer 1997 72 ... [Pg.786]

Urokinase plasminogen activator (uPA)/plasminogen activator inhibitor (PAI-1) are part of the plasminogen activating system, which includes the receptor for uPA and other inhibitors (PAI-2 and PAI-3). This system has been shown experimentally to be associated with invasion, angiogenesis, and metastasis.Low levels of both markers are associated with a sufficiently low risk of recurrence (especially in HR-positive women who will receive adjuvant endocrine therapy) that chemotherapy will only contribute minimal additional benefit. Furthermore, Cytoxan-, methotrexate-, and... [Pg.808]

Jl. Jensen, M. K., Riisbro, R., Holten-Andersen, M. N., et al.. Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders Correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. Eur. J. Haematol. 71, 276-282 (2003). [Pg.128]

Ol. Odet, F., Guyot, R., Leduque, P., and Le Margueresse-Battistoni, B., Evidence for similar expression of protein C inhibitor and the urokinase-type plasminogen activator system during mouse testis development. Endocrinology 145, 1481-1489 (2004). [Pg.130]

Tran-Thang C, Kruithof E, Lahm H, Schuster WA, Tada M, Sordat B (1996) Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells. Br J Cancer 74 846-852 Trikha M, Corringham R, Klein B, Rossi JF (2003) Targeted antiinterleukin-6 monoclonal antibody therapy for cancer a review of the rationale and clinical evidence. Clin Cancer Res 9 4653-4665... [Pg.354]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...